Equities research analysts expect that Zafgen Inc (NASDAQ:ZFGN) will announce earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zafgen’s earnings. Zafgen posted earnings per share of ($0.39) during the same quarter last year, which suggests a positive year-over-year growth rate of 51.3%. The business is expected to announce its next quarterly earnings results on Monday, March 9th.
According to Zacks, analysts expect that Zafgen will report full-year earnings of ($1.21) per share for the current year. For the next year, analysts forecast that the company will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.13) to ($0.74). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Zafgen.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.03.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC lifted its position in Zafgen by 2.2% in the second quarter. Citadel Advisors LLC now owns 971,818 shares of the biopharmaceutical company’s stock valued at $1,156,000 after purchasing an additional 20,953 shares during the last quarter. AWM Investment Company Inc. lifted its position in shares of Zafgen by 32.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock worth $2,210,000 after purchasing an additional 454,874 shares during the period. Morgan Stanley lifted its position in shares of Zafgen by 150.8% in the 2nd quarter. Morgan Stanley now owns 184,606 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 110,989 shares during the period. Wedbush Securities Inc. lifted its position in shares of Zafgen by 122.2% in the 3rd quarter. Wedbush Securities Inc. now owns 170,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 93,500 shares during the period. Finally, Northeast Financial Consultants Inc bought a new stake in shares of Zafgen during the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 61.52% of the company’s stock.
NASDAQ:ZFGN traded up $0.01 during mid-day trading on Wednesday, reaching $0.80. The stock had a trading volume of 3,247 shares, compared to its average volume of 338,672. The stock has a market capitalization of $30.27 million, a P/E ratio of -0.43 and a beta of -0.56. The firm has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.11 and a current ratio of 5.11. Zafgen has a one year low of $0.63 and a one year high of $5.76.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Further Reading: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.